N-[[(5S)-3-[4-(1,4-diazepan-1-yl)-3-fluorophenyl]-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide | 392660-35-4

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N-[[(5S)-3-[4-(1,4-diazepan-1-yl)-3-fluorophenyl]-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide
• CAS: 392660-35-4
• 化学式: C₁₇H₂₃FN₄O₃
• 分子量: 350.393
• InChiKey: QIWYMCOAIGKHNR-AWEZNQCLSA-N

物化性质

• 沸点：
  594.6±50.0 °C(Predicted)
• 密度：
  1.243±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  25
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  73.9
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  N-[[(5S)-3-[4-(1,4-diazepan-1-yl)-3-fluorophenyl]-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide 、 2-氯甲基-5-硝基-呋喃 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 N-[[(5S)-3-[3-fluoro-4-[4-[(5-nitrofuran-2-yl)methyl]-1,4-diazepan-1-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide
  参考文献：
  名称：

  Synthesis and SAR of novel oxazolidinones: Discovery of ranbezolid

  摘要：

  Novel oxazolidinones were synthesized containing a number of substituted five-membered heterocycles attached to the 'piperazinyl-phenyl-oxazolidinone' core of eperezolid. Further, the piperazine ring of the core was replaced by other diamino-heterocycles. These modifications led to several compounds with potent activity against a spectrum of resistant and susceptible Gram-positive organisms, along with the identification of ranbezolid (RBx 7644) as a clinical candidate. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.06.063
• 作为产物：
  描述：

  3,4-二氟硝基苯 在 palladium on activated charcoal 正丁基锂 、 sodium azide 、 TEA 、 氢气 、 碳酸氢钠 、 N,N-二异丙基乙胺 、 三氟乙酸 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 、 乙腈 为溶剂， -78.0~80.0 ℃ 、379.21 kPa 条件下， 反应 1.5h， 生成 N-[[(5S)-3-[4-(1,4-diazepan-1-yl)-3-fluorophenyl]-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide
  参考文献：
  名称：

  Synthesis and SAR of novel oxazolidinones: Discovery of ranbezolid

  摘要：

  Novel oxazolidinones were synthesized containing a number of substituted five-membered heterocycles attached to the 'piperazinyl-phenyl-oxazolidinone' core of eperezolid. Further, the piperazine ring of the core was replaced by other diamino-heterocycles. These modifications led to several compounds with potent activity against a spectrum of resistant and susceptible Gram-positive organisms, along with the identification of ranbezolid (RBx 7644) as a clinical candidate. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.06.063

文献信息

• [EN] OXAZOLIDINONE DERIVATIVES AS ANTIMICROBIALS<br/>[FR] DERIVES D'OXAZOLIDINONE UTILISES COMME AGENTS ANTIMICROBIENS
  申请人：RANBAXY LAB LTD

  公开号：WO2004014392A1

  公开（公告）日：2004-02-19

  The present invention relates to certain substituted phenyl oxazolidinones and to processes for the synthesis of the same. This invention also relates to pharmaceutical compositions containing the compounds of the present invention as antimicrobials. The compounds are useful antimicrobial agents, effective against a number of human and veterinary pathogens, including gram-positive aerobic bacteria such as multiple-resistant staphylococci, streptococci and enterococci as well as anaerobic organisms such as Bacterioides spp. and Clostridia spp. species, and acid fast organisms such as Mycobacterium tuberculosis, Mycobacterium avium and Mycobacterium spp.

  本发明涉及某些取代苯基噁唑烷酮及其合成方法。本发明还涉及含有本发明化合物作为抗微生物剂的药物组合物。这些化合物是有用的抗微生物剂，对许多人类和兽医病原体具有有效作用，包括革兰氏阳性的好氧菌，如多重耐药葡萄球菌、链球菌和肠球菌，以及厌氧菌，如拟杆菌属和梭菌属菌种，以及酸性快速菌，如结核分枝杆菌、非结核分枝杆菌和分枝杆菌属菌种。
• Oxazolidinone derivatives as antimicrobials
  申请人：Mehta Anita

  公开号：US20060293307A1

  公开（公告）日：2006-12-28

  The present invention relates to certain substituted phenyl oxazolidinones and to processes for the synthesis of the same. This invention also relates to pharmaceutical compositions containing the compounds of the present invention as antimicrobials. The compounds are useful antimicrobial agents, effective against a number of human and veterinary pathogens, including gram-positive aerobic bacteria such as multiple-resistant staphylococci, streptococci and enterococci as well as anaerobic organisms such as Bacterioides spp. and Clostridia spp. species, and acid fast organisms such as Mycobacterium tuberculosis, Mycobacterium avium and Mycobacterium spp.

  本发明涉及某些取代苯基噁唑烷酮以及其合成方法。本发明还涉及含有本发明化合物作为抗微生物药物的制药组合物。这些化合物是有用的抗微生物剂，对许多人类和兽医病原体具有有效作用，包括革兰氏阳性的需氧菌，如多重耐药葡萄球菌、链球菌和肠球菌，以及厌氧菌，如Bacterioides属和Clostridiaspp.种，以及酸性快速生长菌，如结核分枝杆菌、埃维菌分枝杆菌和分枝杆菌属。
• OXAZOLIDINONE DERIVATIVES AS ANTIMICROBIALS
  申请人：RANBAXY LABORATORIES, LTD.

  公开号：EP1542696A1

  公开（公告）日：2005-06-22
• EP1542696A4
  申请人：——

  公开号：EP1542696A4

  公开（公告）日：2006-08-02
• Synthesis and SAR of novel oxazolidinones: Discovery of ranbezolid
  作者：Biswajit Das、Sonali Rudra、Ajay Yadav、Abhijit Ray、A.V.S. Raja Rao、A.S.S.V. Srinivas、Ajay Soni、Suman Saini、Shalini Shukla、Manisha Pandya、Pragya Bhateja、Sunita Malhotra、Tarun Mathur、S.K. Arora、Ashok Rattan、Anita Mehta

  DOI：10.1016/j.bmcl.2005.06.063

  日期：2005.10

  Novel oxazolidinones were synthesized containing a number of substituted five-membered heterocycles attached to the 'piperazinyl-phenyl-oxazolidinone' core of eperezolid. Further, the piperazine ring of the core was replaced by other diamino-heterocycles. These modifications led to several compounds with potent activity against a spectrum of resistant and susceptible Gram-positive organisms, along with the identification of ranbezolid (RBx 7644) as a clinical candidate. (c) 2005 Elsevier Ltd. All rights reserved.